Figure 1.
Strategy and antigens in the RCR complex used in single, double, and triple combinations to determine immunogenicity and ability to block P. falciparum growth. (A) Workflow of experiments to determine immunogenicity and development of growth inhibitory antibodies for the RCR complex. Adjuvants and antigen dose were determined prior to immunisation experiments using combinations of RH5.1, CyRPA and Ripr. (B) Schematic of recombinantly expressed proteins expressed with C-terminal affinity tags. RH5.1 (RH5) and CyRPA were expressed with a C-tag (EPEA) (purple) and Ripr was expressed with a StrepII tag (green) for purification. CyRPA and RH5 sequences were modified from the 3D7 wildtype sequence (at numbered positions) to remove potential N-linked glycosylation sites. RH5.1 and Ripr were expressed in S2 Drosophila cells, whereas CyRPA was expressed in mammalian HEK293 cells. (C) RH5.1, CyRPA and Ripr and RCR complex purified antigens analysed by SDS-PAGE and Coomassie staining to visualize the bands.